vs
Freedom Holding Corp.（FRHC）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Freedom Holding Corp.的季度营收约是Royalty Pharma plc的1.0倍（$628.6M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 12.1%，领先22.3%），Royalty Pharma plc同比增速更快（4.8% vs -4.1%），过去两年Freedom Holding Corp.的营收复合增速更高（16.3% vs 4.6%）
Freedom Holding Corp.是在美国内华达州注册的投资集团，业务覆盖零售证券经纪交易、资产管理、资本市场服务、投研咨询、投行承销、抵押贷款、保险、银行及其他消费金融服务，核心布局美股、欧洲及以哈萨克斯坦为核心的中亚市场。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
FRHC vs RPRX — 直观对比
营收规模更大
FRHC
是对方的1.0倍
$622.0M
营收增速更快
RPRX
高出8.8%
-4.1%
净利率更高
RPRX
高出22.3%
12.1%
两年增速更快
FRHC
近两年复合增速
4.6%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $628.6M | $622.0M |
| 净利润 | $76.2M | $214.2M |
| 毛利率 | 96.0% | — |
| 营业利润率 | 14.9% | 62.4% |
| 净利率 | 12.1% | 34.4% |
| 营收同比 | -4.1% | 4.8% |
| 净利润同比 | -2.6% | 2.9% |
| 每股收益（稀释后） | $1.25 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FRHCRPRX
| Q4 25 | $628.6M | $622.0M | ||
| Q3 25 | $526.1M | $609.3M | ||
| Q2 25 | $533.4M | $578.7M | ||
| Q1 25 | $363.7M | $568.2M | ||
| Q4 24 | $655.2M | $593.6M | ||
| Q3 24 | $580.9M | $564.7M | ||
| Q2 24 | $450.7M | $537.3M | ||
| Q1 24 | $464.7M | $568.0M |
净利润FRHCRPRX
| Q4 25 | $76.2M | $214.2M | ||
| Q3 25 | $38.7M | $288.2M | ||
| Q2 25 | $30.4M | $30.2M | ||
| Q1 25 | $-142.7M | $238.3M | ||
| Q4 24 | $78.3M | $208.2M | ||
| Q3 24 | $114.7M | $544.0M | ||
| Q2 24 | $34.4M | $102.0M | ||
| Q1 24 | $95.2M | $4.8M |
毛利率FRHCRPRX
| Q4 25 | 96.0% | — | ||
| Q3 25 | 97.1% | — | ||
| Q2 25 | 97.4% | — | ||
| Q1 25 | 96.6% | — | ||
| Q4 24 | 98.6% | — | ||
| Q3 24 | 99.1% | — | ||
| Q2 24 | 99.0% | — | ||
| Q1 24 | — | — |
营业利润率FRHCRPRX
| Q4 25 | 14.9% | 62.4% | ||
| Q3 25 | 11.5% | 70.1% | ||
| Q2 25 | 7.6% | 36.3% | ||
| Q1 25 | -42.7% | 94.0% | ||
| Q4 24 | 15.0% | 60.9% | ||
| Q3 24 | 22.1% | — | ||
| Q2 24 | 9.2% | 50.2% | ||
| Q1 24 | 22.5% | -13.0% |
净利率FRHCRPRX
| Q4 25 | 12.1% | 34.4% | ||
| Q3 25 | 7.4% | 47.3% | ||
| Q2 25 | 5.7% | 5.2% | ||
| Q1 25 | -39.2% | 41.9% | ||
| Q4 24 | 11.9% | 35.1% | ||
| Q3 24 | 19.7% | 96.3% | ||
| Q2 24 | 7.6% | 19.0% | ||
| Q1 24 | 20.5% | 0.8% |
每股收益（稀释后）FRHCRPRX
| Q4 25 | $1.25 | $0.49 | ||
| Q3 25 | $0.63 | $0.67 | ||
| Q2 25 | $0.50 | $0.07 | ||
| Q1 25 | $-2.35 | $0.55 | ||
| Q4 24 | $1.29 | $0.46 | ||
| Q3 24 | $1.89 | $1.21 | ||
| Q2 24 | $0.57 | $0.23 | ||
| Q1 24 | $1.60 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $869.2M | $618.7M |
| 总债务越低越好 | — | $9.0B |
| 股东权益账面价值 | $1.4B | $9.7B |
| 总资产 | $12.4B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资FRHCRPRX
| Q4 25 | $869.2M | $618.7M | ||
| Q3 25 | $636.0M | $938.9M | ||
| Q2 25 | $567.9M | $631.9M | ||
| Q1 25 | $837.3M | $1.1B | ||
| Q4 24 | $577.9M | $929.0M | ||
| Q3 24 | $569.2M | $950.1M | ||
| Q2 24 | $718.7M | $1.8B | ||
| Q1 24 | $545.1M | $843.0M |
总债务FRHCRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益FRHCRPRX
| Q4 25 | $1.4B | $9.7B | ||
| Q3 25 | $1.2B | $9.6B | ||
| Q2 25 | $1.2B | $9.5B | ||
| Q1 25 | $1.2B | $9.8B | ||
| Q4 24 | $1.3B | $10.3B | ||
| Q3 24 | $1.3B | $10.3B | ||
| Q2 24 | $1.1B | $9.8B | ||
| Q1 24 | $1.2B | $9.9B |
总资产FRHCRPRX
| Q4 25 | $12.4B | $19.6B | ||
| Q3 25 | $10.3B | $19.3B | ||
| Q2 25 | $9.7B | $18.3B | ||
| Q1 25 | $9.9B | $17.6B | ||
| Q4 24 | $9.1B | $18.2B | ||
| Q3 24 | $8.8B | $18.0B | ||
| Q2 24 | $8.5B | $17.7B | ||
| Q1 24 | $8.3B | $16.1B |
负债/权益比FRHCRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $717.8M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $651.7M | — |
| 自由现金流率自由现金流/营收 | 103.7% | — |
| 资本支出强度资本支出/营收 | 10.5% | — |
| 现金转化率经营现金流/净利润 | 9.42× | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流FRHCRPRX
| Q4 25 | $717.8M | $827.1M | ||
| Q3 25 | $535.3M | $702.6M | ||
| Q2 25 | $480.8M | $364.0M | ||
| Q1 25 | $1.3B | $596.1M | ||
| Q4 24 | $-72.8M | $742.5M | ||
| Q3 24 | $-438.0M | $703.6M | ||
| Q2 24 | $854.1M | $658.2M | ||
| Q1 24 | $309.0M | $664.6M |
自由现金流FRHCRPRX
| Q4 25 | $651.7M | — | ||
| Q3 25 | $456.4M | — | ||
| Q2 25 | $450.0M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-92.7M | — | ||
| Q3 24 | $-447.5M | — | ||
| Q2 24 | $829.9M | — | ||
| Q1 24 | — | — |
自由现金流率FRHCRPRX
| Q4 25 | 103.7% | — | ||
| Q3 25 | 86.7% | — | ||
| Q2 25 | 84.4% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -14.1% | — | ||
| Q3 24 | -77.0% | — | ||
| Q2 24 | 184.1% | — | ||
| Q1 24 | — | — |
资本支出强度FRHCRPRX
| Q4 25 | 10.5% | — | ||
| Q3 25 | 15.0% | — | ||
| Q2 25 | 5.8% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 3.0% | — | ||
| Q3 24 | 1.6% | — | ||
| Q2 24 | 5.4% | — | ||
| Q1 24 | — | — |
现金转化率FRHCRPRX
| Q4 25 | 9.42× | 3.86× | ||
| Q3 25 | 13.82× | 2.44× | ||
| Q2 25 | 15.82× | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | -0.93× | 3.57× | ||
| Q3 24 | -3.82× | 1.29× | ||
| Q2 24 | 24.83× | 6.45× | ||
| Q1 24 | 3.24× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FRHC
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
